Themis preps first clinical test of oncolytic viral approach with €40M round

As Themis continues to develop vaccines using its measles viral vectors to treat infectious diseases, the Austrian biotech also hopes to use its new €40 million ($44.3 million) series D round to conduct its first clinical study applying its platform in immuno-oncology.

“Almost all cancer cells overexpress a specific receptor, CD46, and measles happens to meet this entry point,” Themis CEO Erich Tauber told BioCentury. The company will first test its virus-based treatments in colorectal cancer, beginning this year...